Latest & greatest articles for constipation

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on constipation or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on constipation and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for constipation

81. Linaclotide (Constella) - Symptomatic treatment of moderate to severe irritable bowel syndrome with constipation (IBS-C) in adults

Linaclotide (Constella) - Symptomatic treatment of moderate to severe irritable bowel syndrome with constipation (IBS-C) in adults

Scottish Medicines Consortium2013

82. Sacral nerve stimulation for constipation

Sacral nerve stimulation for constipation 23124687 2012 12 14 2013 02 19 2012 12 14 1365-2168 100 2 2013 Jan The British journal of surgery Br J Surg Sacral nerve stimulation for constipation. 174-81 10.1002/bjs.8944 For over 10 years sacral nerve stimulation (SNS) has been used for patients with constipation resistant to conservative treatment. A review of the literature is presented. PubMed, MEDLINE and Embase databases were searched for studies demonstrating the use of SNS for the treatment (...) of constipation. Thirteen studies have been published describing the results of SNS for chronic constipation. Of these, three were in children and ten in adults. Test stimulation was successful in 42-100 per cent of patients. In those who proceeded to permanent SNS, up to 87 per cent showed an improvement in symptoms at a median follow-up of 28 months. The success of stimulation varied depending on the outcome measure being used. Symptom improvement correlated with improvement in quality of life and patient

EvidenceUpdates2013

83. Irritable bowel syndrome with constipation in adults: linaclotide

Irritable bowel syndrome with constipation in adults: linaclotide Irritable bowel syndrome with constipation in Irritable bowel syndrome with constipation in adults: linaclotide adults: linaclotide Evidence summary Published: 9 April 2013 nice.org.uk/guidance/esnm16 pathways Ov Overview erview The content of this evidence summary was up-to-date in April 2013. See summaries of product characteristics (SPCs), British national formulary (BNF) or the MHRA or NICE websites for up- to-date (...) information. Key points from the evidence Linaclotide (Constella) is a first-in-class, oral, once-daily guanylate cyclase-C receptor agonist (GCCA), licensed for the symptomatic treatment of moderate-to-severe irritable bowel syndrome with constipation (IBS-C) in adults. It received a European marketing authorisation in November 2012 and is expected to be launched during the first half of 2013. Linaclotide has been evaluated in 2 double-blind, randomised, placebo-controlled trials of patients with IBS-C

National Institute for Health and Clinical Excellence - Advice2013

84. Constipation

Constipation Constipation Email Address Password Remember me Not a member? Article Constipation 2015-04-15 17:52:25 UTC | ---- Figure 1 Treatment algorithm for chronic constipation. MR, magnetic resonance. ---- | ---- Figure 2 Treatment algorithm for NTC and STC. PEG, polyethylene glycol; MOM, milk of magnesia; GI, gastrointestinal. ---- | Figure 3 Treatment algorithm for defecating disorders. MR, magnetic resonance; p.r.n., as needed. Hide Pane Expand all Collapse all Article Outline (...) Abbreviations used in this paper: ( ), ( ), ( ), ( ) Podcast interview: . Also available on iTunes. This document presents the official recommendations of the American Gastroenterological Association (AGA) on constipation. It was drafted by the AGA Institute Medical Position Panel, reviewed by the Clinical Practice and Quality Management Committee, and approved by the AGA Institute Governing Board. This medical position statement is published in conjunction with a technical review x Bharucha, A.E

American Gastroenterological Association Institute2013

85. Coping with Common GI Symptoms in the Community: A Global Perspective on Heartburn, Constipation, Bloating, and Abdominal Pain/Discomfort

Coping with Common GI Symptoms in the Community: A Global Perspective on Heartburn, Constipation, Bloating, and Abdominal Pain/Discomfort © World Gastroenterology Organisation, 2013 World Gastroenterology Organisation Global Guidelines Coping with common GI symptoms in the community A global perspective on heartburn, constipation, bloating, and abdominal pain/discomfort May 2013 Review Team Richard Hunt (co-chair, Canada/UK) Eamonn Quigley (co-chair, USA) Zaigham Abbas (Pakistan) Abraham (...) 4.6.3 Primary care doctor 23 4.6.4 Specialist 24 5 Bloating 25 5.1 Definition and description 25 5.2 Epidemiological notes 26 5.3 Diagnostic/symptoms remarks 26 5.4 Differential diagnosis 27 5.5 Alarm features 27 5.6 Bloating—management cascade 27 5.6.1 Bloating self-help 27 5.6.2 Pharmacist 28 5.6.3 Primary care doctor 28 5.6.4 Specialist 29 6 Constipation 29 WGO Global Guidelines Common GI symptoms (long version) 3 © World Gastroenterology Organisation, 2013 6.1 Definition and description 29 6.2

World Gastroenterology Organisation2013

86. Lubiprostone (Amitiza) for chronic idiopathic constipation

Lubiprostone (Amitiza) for chronic idiopathic constipation Lubiprostone (Amitiza) for chronic idiopathic constipation Lubiprostone (Amitiza) for chronic idiopathic constipation NIHR HSC Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation NIHR HSC. Lubiprostone (Amitiza) for chronic idiopathic constipation. Birmingham: NIHR Horizon Scanning (...) Centre (NIHR HSC). Horizon Scanning Review. 2012 Final publication URL Indexing Status Subject indexing assigned by CRD MeSH Alprostadil; Chronic Disease; Constipations Language Published English Country of organisation England English summary An English language summary is available. Address for correspondence The NIHR Horizon Scanning Centre, Department of Public Health, Epidemiology, and Biostatistics, School of Health and Population Sciences, University of Birmingham, 90 Vincent Drive, Edgbaston

Health Technology Assessment (HTA) Database.2012

87. Lubiprostone (Amitiza) for opioid-induced constipation in patients with chronic non-cancer pain

Lubiprostone (Amitiza) for opioid-induced constipation in patients with chronic non-cancer pain Lubiprostone (Amitiza) for opioid-induced constipation in patients with chronic non-cancer pain Lubiprostone (Amitiza) for opioid-induced constipation in patients with chronic non-cancer pain NIHR HSC Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database (...) . Citation NIHR HSC. Lubiprostone (Amitiza) for opioid-induced constipation in patients with chronic non-cancer pain. Birmingham: NIHR Horizon Scanning Centre (NIHR HSC). Horizon Scanning Review. 2012 Final publication URL Indexing Status Subject indexing assigned by CRD MeSH Alprostadils; Chronic Pain; Constipation Language Published English Country of organisation England English summary An English language summary is available. Address for correspondence The NIHR Horizon Scanning Centre, Department

Health Technology Assessment (HTA) Database.2012

88. A 12-Week, Randomized, Controlled Trial With a 4-Week Randomized Withdrawal Period to Evaluate the Efficacy and Safety of Linaclotide in Irritable Bowel Syndrome With Constipation

A 12-Week, Randomized, Controlled Trial With a 4-Week Randomized Withdrawal Period to Evaluate the Efficacy and Safety of Linaclotide in Irritable Bowel Syndrome With Constipation 22986440 2013 01 08 2013 02 11 2015 02 23 1572-0241 107 11 2012 Nov The American journal of gastroenterology Am. J. Gastroenterol. A 12-week, randomized, controlled trial with a 4-week randomized withdrawal period to evaluate the efficacy and safety of linaclotide in irritable bowel syndrome with constipation. 1714-24 (...) ; quiz p.1725 Linaclotide is a minimally absorbed guanylate cyclase-C agonist. The objective of this trial was to determine the efficacy and safety of linaclotide in patients with irritable bowel syndrome with constipation (IBS-C). This phase 3, double-blind, parallel-group, placebo-controlled trial randomized IBS-C patients to placebo or 290 μ g oral linaclotide once daily in a 12-week treatment period, followed by a 4-week randomized withdrawal (RW) period. There were four primary end points

EvidenceUpdates2012 Full Text: Link to full Text with Trip Pro

89. Linaclotide for Irritable Bowel Syndrome With Constipation: A 26-Week, Randomized, Double-blind, Placebo-Controlled Trial to Evaluate Efficacy and Safety

Linaclotide for Irritable Bowel Syndrome With Constipation: A 26-Week, Randomized, Double-blind, Placebo-Controlled Trial to Evaluate Efficacy and Safety 22986437 2013 01 08 2013 02 11 2014 03 07 1572-0241 107 11 2012 Nov The American journal of gastroenterology Am. J. Gastroenterol. Linaclotide for irritable bowel syndrome with constipation: a 26-week, randomized, double-blind, placebo-controlled trial to evaluate efficacy and safety. 1702-12 Linaclotide is a minimally absorbed peptide (...) guanylate cyclase-C agonist. The objective of this trial was to determine the efficacy and safety of linaclotide treatment in patients with irritable bowel syndrome with constipation (IBS-C) over 26 weeks. This phase 3, double-blind, parallel-group, placebo-controlled trial randomized IBS-C patients to placebo or 290 μg of oral linaclotide once daily for a 26-week treatment period. The primary and the secondary efficacy assessments were evaluated over the first 12 weeks of treatment. Primary end points

EvidenceUpdates2012

90. Naloxegol (NKTR-118) for opioid-induced constipation

Naloxegol (NKTR-118) for opioid-induced constipation Naloxegol (NKTR-118) for opioid-induced constipation Naloxegol (NKTR-118) for opioid-induced constipation NHSC Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation NHSC. Naloxegol (NKTR-118) for opioid-induced constipation. Birmingham: National Horizon Scanning Centre (NHSC). Horizon (...) Scanning Review. 2012 Final publication URL Indexing Status Subject indexing assigned by CRD MeSH Analgesics, Opioids; Constipation; Laxatives; Naltrexone Language Published English Country of organisation England English summary An English language summary is available. Address for correspondence The NIHR Horizon Scanning Centre, Department of Public Health, Epidemiology, and Biostatistics, School of Health and Population Sciences, University of Birmingham, 90 Vincent Drive, Edgbaston, Birmingham, B15

Health Technology Assessment (HTA) Database.2012

92. Management of Opioid-Induced Constipation in Chronic Pain Patients

Management of Opioid-Induced Constipation in Chronic Pain Patients

RxFiles2012

93. Wireless motility capsule in the diagnosis and evaluation of gastroparesis or slow-transit constipation

Wireless motility capsule in the diagnosis and evaluation of gastroparesis or slow-transit constipation Wireless motility capsule in the diagnosis and evaluation of gastroparesis or slow-transit constipation Wireless motility capsule in the diagnosis and evaluation of gastroparesis or slow-transit constipation BlueCross BlueShield Association Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made (...) for the HTA database. Citation BlueCross BlueShield Association. Wireless motility capsule in the diagnosis and evaluation of gastroparesis or slow-transit constipation. Chicago: BlueCross BlueShield Association (BCBS). TEC Assessment 27(4). 2012 Authors' objectives The objective of this assessment is to determine whether the wireless motility capsule (SmartPill®) improves health outcomes when used in the diagnosis and evaluation of gastroparesis and constipation, in patients presenting with clinical

Health Technology Assessment (HTA) Database.2012

94. Overactive bladder drugs and constipation: a meta-analysis of randomized, placebo-controlled trials

Overactive bladder drugs and constipation: a meta-analysis of randomized, placebo-controlled trials Overactive bladder drugs and constipation: a meta-analysis of randomized, placebo-controlled trials Overactive bladder drugs and constipation: a meta-analysis of randomized, placebo-controlled trials Meek PD, Evang SD, Tadrous M, Roux-Lirange D, Triller DM, Gumustop B CRD summary The review concluded that patients prescribed anticholinergic drugs for overactive bladder were significantly more (...) likely to experience constipation. This was a relatively well-conducted review and the authors' conclusion is likely to be reliable. Authors' objectives To determine constipation rates in patients receiving anticholinergic drugs compared with placebo for the treatment of overactive bladder. Searching MEDLINE and the Cochrane Library were searched from 1966 to December 2009; search terms were reported. The US Food and Drug Administration (FDA) website was searched up to April 3, 2010 for studies

DARE.2011

95. Effect of laxatives and pharmacological therapies in chronic idiopathic constipation: systematic review and meta-analysis

Effect of laxatives and pharmacological therapies in chronic idiopathic constipation: systematic review and meta-analysis Effect of laxatives and pharmacological therapies in chronic idiopathic constipation: systematic review and meta-analysis Effect of laxatives and pharmacological therapies in chronic idiopathic constipation: systematic review and meta-analysis Ford AC, Suares NC CRD summary The review found that laxatives, prucalopride, lubiprostone and linaclotide were all more effective (...) than placebo for short-term treatment of chronic idiopathic constipation, but were associated with a greater frequency of diarrhoea. The authors' appropriate conclusions reflect the evidence base and are likely to be reliable. Authors' objectives To assess the effect of laxatives and pharmacological therapies in chronic idiopathic constipation. Searching MEDLINE (from 1950), EMBASE (from 1947) and Cochrane Central Register of Controlled Trials (CENTRAL) were searched to September 2010. There were

DARE.2011

97. Linaclotide improves abdominal pain and bowel habits in a phase IIb study of patients with irritable bowel syndrome with constipation

Linaclotide improves abdominal pain and bowel habits in a phase IIb study of patients with irritable bowel syndrome with constipation 20801122 2010 12 03 2011 01 04 2010 12 03 1528-0012 139 6 2010 Dec Gastroenterology Gastroenterology Linaclotide improves abdominal pain and bowel habits in a phase IIb study of patients with irritable bowel syndrome with constipation. 1877-1886.e2 10.1053/j.gastro.2010.08.041 Linaclotide, a minimally absorbed, 14-amino acid peptide agonist of guanylate cyclase-C (...) , has shown benefit in a proof-of-concept study for the treatment of patients with irritable bowel syndrome (IBS) with constipation (IBS-C). We assessed the efficacy and safety of linaclotide at a daily dose range of 75-600 μg in IBS-C. We performed a randomized, double-blind, multicenter, placebo-controlled study of 420 patients with IBS-C given oral linaclotide at doses of 75, 150, 300, or 600 μg or placebo once daily for 12 weeks. End points included change from baseline in daily bowel habits

EvidenceUpdates2011

98. Systematic review: Polyethylene glycol more effective than lactulose for relief of chronic constipation

Systematic review: Polyethylene glycol more effective than lactulose for relief of chronic constipation Polyethylene glycol more effective than lactulose for relief of chronic constipation | Evidence-Based Nursing This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Log in via your Society Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search (...) for this keyword Search for this keyword Main menu Log in via your Society Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Polyethylene glycol more effective than lactulose for relief of chronic constipation Article Text Primary health care Systematic review Polyethylene glycol more effective than lactulose for relief of chronic constipation Marion Allison Statistics from Altmetric.com

Evidence-Based Nursing (Requires free registration)2011

100. Managing functional constipation in children

Managing functional constipation in children Managing functional constipation in children | Position statements and practice points | Managing functional constipation in children | Canadian Paediatric Society Protecting and promoting the health and well-being of children and youth CPS Member Login | Who We Are What We Do Get Involved Education/CPD Publications Careers > Share PRACTICE POINT Managing functional constipation in children Posted: Dec 1 2011 Reaffirmed: Feb 1 2016 The Canadian (...) Paediatric Society gives permission to print single copies of this document from our website. For permission to reprint or reproduce multiple copies, please see our . Principal author(s) A Rowan-Legg; Canadian Paediatric Society , Paediatr Child Health 2011;16(10):661-5 Abstract Constipation is a common childhood problem, with both somatic and psychological effects. The etiology of paediatric constipation is likely multifactorial, and seldom due to organic pathology. Children benefit from prompt

Canadian Paediatric Society2011